Industry Disappointed With England’s Proposed Approach To Innovative Medicines Fund
Initial optimism about the prospects of speeding up access to rare disease treatments through a new £340m dedicated fund has waned as companies question whether the detailed proposals are workable in practice.
You may also be interested in...
Stakeholders are calling for NHS England and NHS Improvement (NHSE&I) and the health technology assessment body NICE to bring more flexibility into England’s new Innovative Medicines Fund, which is due for launch later in 2021.
England’s health technology assessment institute is exploring solutions to help deal with its increased workload, high staff turnover and challenges in recruiting people with the expertise needed.
Questions are being raised about the credibility of the UK’s voluntary and statutory drug pricing schemes because of uncertainty over the payment percentages companies will have to pay in future.